In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Agios nets $516mm through public offering

24 Jan 2018

Executive Summary

Agios Pharmaceuticals Inc. (therapies for cancer and rare genetic diseases) netted $516mm through a public offering of 8.1mm common shares (including the overallotment) at $67. Proceeds will support the company's pipeline activities, including late-stage development, approval, and commercial launch of ivosidenib for acute myeloid leukemia and solid tumors, and planned trials with AG348 for PK deficiency and thalassemia.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By